Alnylam Pharmaceuticals, Inc.
NASDAQAlnylam Pharmaceuticals heads into its October 29 earnings report with short interest climbing steadily for the past month and the Street divided on where the stock goes next, while the company trades roughly a third below the average analyst target. Short interest has rebuilt sharply in September. Positions are now 37% larger than they were a month ago, reaching 5.5% of the free…
ALNY short interest surges 25% in one day to 5.1% of float, marking sharpest single-session jump in recent weeks as availability plummets to 1,754% amid biotech volatility.
Alnylam Pharmaceuticals heads into its October 29 earnings report with short interest climbing steadily for the past month and the Street divided on where the stock goes next, while the company trades roughly a third…
ALNY has clawed back 20% in a month to $246, yet the gap between where the stock trades and where analysts think it should be remains the defining tension heading into October earnings. The recovery since the August…
Snapshot as of 4 Oct 2026
ALNY enters the final stretch of the year with a striking disconnect at its core: a stock down nearly 18% in a month, trading at $237, yet carrying a Street consensus price target of $370 — an implied upside of around…
Alnylam Pharmaceuticals enters the back half of August carrying scars from a brutal July earnings print — and a Street that remains constructive but is methodically resetting its expectations lower. The tension is…
Alnylam Pharmaceuticals reports again on August 6 — just one week after the 28% collapse that made its July 30 print one of the most punishing single-day moves in the stock's history. The options market is telling a…
Alnylam Pharmaceuticals just delivered the worst single-day drop in recent memory, collapsing 28% on July 30 to $205.48 after its earnings print triggered an immediate and sweeping analyst response. The catalyst was…
Alnylam Pharmaceuticals heads into its July 30 earnings print with the Street broadly bullish but steadily marking down its price targets — a week after the stock shed 3.5% to $271.37. The analyst picture is the…
Alnylam Pharmaceuticals enters the week with its most bullish options configuration of the past year, even as the short-side rebuild that defined early June quietly goes into reverse. The standout this week is in the…
Alnylam Pharmaceuticals enters June with a fresh tension: short sellers are quietly rebuilding positions in a stock the analyst consensus still rates a Buy — but where the share price sits $160 below the average Street…
Alnylam Pharmaceuticals heads into its Q1 2026 earnings today with options traders sending a strikingly bullish signal — the most bullish in at least a year. The put/call ratio dropped to 0.39 on May 19, three standard…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ALNY — free to start on ORTEX.
Sign up for free →Open ALNY on ORTEX